羟基磷灰石纳米粒子体外抗肝癌的实验研究  

Experimental Study on the Effects of Antihepatocarcinoma with Hydroxyapatite Nanoparticles in vitro

作　　者：曹献英[1] 戴红莲[1] 贾莉 王红晖 闫玉华 李世普 

机构地区：[1]武汉理工大学生物中心,湖北武汉430070

出　　处：《肿瘤学杂志》2002年第5期274-276,共3页Journal of Chinese Oncology

基　　金：国家自然科学基金资助项目(39770225)

摘　　要：[目的]研究羟基磷灰石（HAP）纳米粒子对肝癌细胞和肝细胞的选择性作用。[方法]以细胞系Bel-7402人肝癌细胞和大鼠肝细胞为对象,倒置显微镜下观察细胞的生长状态,应用活细胞计数法绘制生长曲线。[结果]经HAP纳米粒子（1.4×10-4mol/L）作用的肝癌细胞与其对照组相比,细胞数量逐渐减少,胞质空泡样变,二者存在显著性差异（P<0.01）。而加入不同浓度HAP纳米粒子的肝细胞组,存活细胞数量明显增多,与对照组之间无明显差异。[结论]HAP纳米粒子有明显的体外抗肝癌作用,而对正常肝细胞影响轻微。[Purpose] To investigate the selective effect of hydroxyapatite (HAP) on hepatocarcinoma cells and hepatocyte. [Methods] Research target with cell line Bel-7402 human hepatoma cells and primary rat hepatocyte cells, growth state of cells were observed by inverted microscope, and growth curve were drawed with living cell counting method. [Results]The number of Bel-7402 cells treated by HAP nanoparticles was obviously fewer than control group(P < 0.01), and there was a lot of vacuoles in cytoplasm of Bel-7402 cells. However, the number of survival hepatocyte cells treated by HAP nanoparticles of different concentration were increasing, and had no significant difference than control group. [Conclusion]HAP nanoparticles can inhibit hepatocarcinoma cells in vitro, but have little effect on normal hepatic cells.

关 键 词：羟基磷灰石 纳米粒子 体外抗肝癌 实验研究 肝肿瘤 

分 类 号：R735.7[医药卫生—肿瘤] R73－36[医药卫生—临床医学]